The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Key Takeaways Moderna reported a larger loss than analysts had expected for the fourth quarter on Friday.The COVID vaccine ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than ...

Reports Q4 revenue $966M, consensus $941.14M. The company reported $923M in Spikevax sales in the fourth quarter of 2024 and $15M in mRESVIA ...

Revenue of $966 million beat analysts' estimates, but was down significantly from $2.81 billion in Q4 2023. The company ... in COVID-19 vaccine sales. Moderna is a biotechnology company primarily ...

Welcome to the Moderna Fourth Quarter 2024 Conference Call ... excluding the resizing charge this would have been 53%. R&D expenses in Q4 were $1.1 billion, reflecting a 20% year-over-year ...